3.38
price down icon7.90%   -0.29
pre-market  プレマーケット:  3.19   -0.19   -5.62%
loading
前日終値:
$3.67
開ける:
$3.73
24時間の取引高:
460.07K
Relative Volume:
2.05
時価総額:
$110.61M
収益:
$1.95M
当期純損益:
$-47.84M
株価収益率:
-2.2789
EPS:
-1.4832
ネットキャッシュフロー:
$-27.46M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-18.16%
6か月 パフォーマンス:
+0.30%
1年 パフォーマンス:
+3.05%
1日の値動き範囲:
Value
$3.19
$3.7566
1週間の範囲:
Value
$3.17
$3.7566
52週間の値動き範囲:
Value
$2.42
$8.51

Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile

Name
名前
Insight Molecular Diagnostics Inc
Name
セクター
Healthcare (1066)
Name
電話
949-409-7600
Name
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Name
職員
58
Name
Twitter
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
IMDX's Discussions on Twitter

Compare IMDX vs TMO, DHR, NTRA, A, WAT

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IMDX icon
IMDX
Insight Molecular Diagnostics Inc
3.38 128.28M 1.95M -47.84M -27.46M -1.4832
TMO icon
TMO
Thermo Fisher Scientific Inc
656.58 241.26B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
215.61 150.48B 24.78B 3.68B 5.29B 5.1743
NTRA icon
NTRA
Natera Inc
400.65 59.47B 2.50B -226.32M 71.51M -1.6412
A icon
A
Agilent Technologies Inc
169.33 48.71B 7.23B 1.41B 1.09B 4.979
WAT icon
WAT
Waters Corp
436.43 42.59B 3.77B 449.25M 240.68M 7.8556

Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-28 開始されました Lake Street Buy
2022-05-24 ダウングレード Stephens Overweight → Equal-Weight
2022-03-14 ダウングレード KeyBanc Capital Markets Overweight → Sector Weight
2022-01-07 開始されました Stephens Overweight
2022-01-06 再開されました Piper Sandler Overweight
2021-03-17 再開されました Needham Buy
2021-01-07 アップグレード The Benchmark Company Speculative Buy → Buy
2020-12-16 アップグレード Piper Sandler Neutral → Overweight
2020-11-30 開始されました BTIG Research Buy
2020-11-10 開始されました KeyBanc Capital Markets Overweight
2020-07-30 繰り返されました The Benchmark Company Speculative Buy
2020-07-01 ダウングレード Piper Sandler Overweight → Neutral
2020-06-30 ダウングレード Chardan Capital Markets Buy → Neutral
2020-06-02 開始されました Needham Buy
2019-02-13 開始されました Piper Jaffray Overweight
2019-01-29 アップグレード Janney Neutral → Buy
2018-12-19 再開されました Lake Street Buy
すべてを表示

Insight Molecular Diagnostics Inc (IMDX) 最新ニュース

pulisher
Sep 21, 2026

Insight Molecular Diagnostics Revises Chronix Royalty Agreement Terms - TipRanks

Sep 21, 2026
pulisher
Sep 21, 2026

Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026 - TradingView

Sep 21, 2026
pulisher
Sep 21, 2026

Insight Molecular Diagnostics Inc. Share PriceIMDX, RNS News, Articles, Quotes, & Charts (NASDAQ:IMDX) - proactiveinvestors.com

Sep 21, 2026
pulisher
Sep 21, 2026

Insight Molecular (IMDX) shifts Chronix earnout to CNI Monitor test - Stock Titan

Sep 21, 2026
pulisher
Sep 20, 2026

Insight Molecular Diagnostics Inc.(NasdaqCM: IMDX) added to S&P Global BMI Index - marketscreener.com

Sep 20, 2026
pulisher
Sep 11, 2026

Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com

Sep 11, 2026
pulisher
Sep 09, 2026

Insight Molecular Diagnostics (IMDX) Stock Price Prediction for 2026, 2030-2040 - Traders Union

Sep 09, 2026
pulisher
Sep 08, 2026

Medicare policy boosts iMDx transplant testing frequency - scanx.trade

Sep 08, 2026
pulisher
Sep 04, 2026

Insight Molecular Diagnostics Inc. (IMDX) Slips 1.94% to $4.04 as Key Support HoldsGamma Squeeze - dars.gov.et

Sep 04, 2026
pulisher
Sep 02, 2026

iMDx executives are set to meet investors in New York - Stock Titan

Sep 02, 2026
pulisher
Sep 02, 2026

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference - GlobeNewswire

Sep 02, 2026
pulisher
Aug 30, 2026

IMDX Q2 2026 Earnings: Wider-than-Expected Loss Sends Shares Down 3.73%Earnings Per Share - careplusvn.com

Aug 30, 2026
pulisher
Aug 24, 2026

Lucid Capital Markets initiates Insight Molecular stock with buy rating By Investing.com - Investing.com Nigeria

Aug 24, 2026
pulisher
Aug 24, 2026

Insight (IMDX) Quarter in Focus: Profit Per Share Clears Its Benchmark on the Day; Shares Move 0.93% Higher on the DayWeak Earnings Momentum - dars.gov.et

Aug 24, 2026
pulisher
Aug 23, 2026

Insight Molecular Diagnostics Earnings Call Balances Risk - TipRanks

Aug 23, 2026
pulisher
Aug 19, 2026

Insight (IMDX) Price: Adds 2.34% to Close at $4.38 in Latest Trading; Price Levels: the $4.16 to $4.60 Range Remains in Focus in the Current UpdateTriangle Correction - vinanet.vn

Aug 19, 2026
pulisher
Aug 19, 2026

Insight (IMDX) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in Latest Trading; Market Read: The Stock Gains 0.23% at the CloseEarnings Surprise Score - vinanet.vn

Aug 19, 2026
pulisher
Aug 18, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 18, 2026
pulisher
Aug 18, 2026

Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo

Aug 18, 2026
pulisher
Aug 18, 2026

IMDX Reiterated by Needham -- Price Target Maintained at $9.00 - GuruFocus

Aug 18, 2026
pulisher
Aug 18, 2026

Needham Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Aug 18, 2026
pulisher
Aug 17, 2026

Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 17, 2026
pulisher
Aug 17, 2026

Insight Molecular Diagnostics advances heart tr... - Pluang

Aug 17, 2026
pulisher
Aug 15, 2026

Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research

Aug 15, 2026
pulisher
Aug 13, 2026

Insight Molecular Diagnostics (IMDX) Drops 6.4% to $4.21 as Sellers Target $4.00 SupportDescending Triangle - dars.gov.et

Aug 13, 2026
pulisher
Aug 13, 2026

Rest-Of-Europe Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets

Aug 13, 2026
pulisher
Aug 13, 2026

Germany Molecular Cytogenetics Market Size, Share,Trends, Growth Analysis Report, 2030 - marketsandmarkets.com

Aug 13, 2026
pulisher
Aug 12, 2026

Insight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform - scanx.trade

Aug 12, 2026
pulisher
Aug 11, 2026

OCX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Aug 11, 2026
pulisher
Aug 11, 2026

Insight Molecular Diagnostics to Host Virtual KOL Event on - GlobeNewswire

Aug 11, 2026
pulisher
Aug 11, 2026

Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 11, 2026
pulisher
Aug 11, 2026

IMDX Looks 284.7% Overvalued on GF Value™ - GuruFocus

Aug 11, 2026
pulisher
Aug 11, 2026

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada

Aug 11, 2026
pulisher
Aug 11, 2026

Insight Molecular Nears FDA Authorization for GraftAssureDx Assay - TipRanks

Aug 11, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Q2 EPS beats as FDA review advances - scanx.trade

Aug 10, 2026
pulisher
Aug 10, 2026

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results - Investing.com Nigeria

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates - Investing.com

Aug 10, 2026
pulisher
Aug 10, 2026

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com - Investing.com South Africa

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics: Q2 Earnings Snapshot - marketscreener.com

Aug 10, 2026
pulisher
Aug 10, 2026

IMDX: FDA review progresses, Medicare expands coverage, and Q2 loss narrows on cost discipline - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash - Stock Titan

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 10, 2026
pulisher
Aug 10, 2026

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx - The Manila Times

Aug 10, 2026
pulisher
Aug 10, 2026

IMDX Q1 2026 Earnings: Narrower-Than-Expected Loss Delivers 55% EPS SurpriseEPS Surprise History - dars.gov.et

Aug 10, 2026
pulisher
Aug 10, 2026

Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Aug 10, 2026
pulisher
Aug 09, 2026

IMDX Looks 289.5% Overvalued on GF Value™ - GuruFocus

Aug 09, 2026
pulisher
Aug 07, 2026

Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView

Aug 07, 2026
pulisher
Aug 07, 2026

Insight Molecular Diagnostics Inc. (7OC0.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Aug 07, 2026
pulisher
Aug 06, 2026

Insight Molecular Diagnostics (IMDX) Slides 3.6% to $4.82: Support Test in FocusMedian Line - careplusvn.com

Aug 06, 2026
pulisher
Aug 05, 2026

IMDX Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView

Aug 05, 2026

Insight Molecular Diagnostics Inc (IMDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Insight Molecular Diagnostics Inc (IMDX) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
BROADWOOD PARTNERS, L.P.
10% Owner
Apr 27 '26
Buy
3.64
250,923
913,134
12,684,884
BROADWOOD PARTNERS, L.P.
10% Owner
Apr 24 '26
Buy
3.53
38,880
137,083
12,433,961
BROADWOOD PARTNERS, L.P.
10% Owner
Apr 16 '26
Buy
3.45
102,057
351,658
12,033,896
BROADWOOD PARTNERS, L.P.
10% Owner
Apr 20 '26
Buy
3.88
40,690
157,967
12,114,700
BROADWOOD PARTNERS, L.P.
10% Owner
Apr 17 '26
Buy
3.57
40,114
143,251
12,074,010
BROADWOOD PARTNERS, L.P.
10% Owner
Feb 10 '26
Buy
5.75
521,739
2,999,999
11,931,839
James Andrea S.
Chief Financial Officer
Oct 31 '25
Option Exercise
0.00
50,000
0
201,231
LH LH
$311.71
price up icon 0.99%
MTD MTD
$1,533.07
price down icon 0.56%
$515.41
price down icon 2.21%
$273.54
price down icon 6.86%
IQV IQV
$259.98
price down icon 2.30%
WAT WAT
$436.43
price down icon 0.84%
大文字化:     |  ボリューム (24 時間):